EVI

What role can vaccines play in combatting antimicrobial resistance? A public-private partnership seeks to answer that question through an open-source, web-based analytic platform, Germany’s European Vaccine Initiative (EVI) announced last week.

The PrIMAVeRa project—coordinated by EVI and backed by $10.3 million from the Brussels-based Innovative Medicines Initiative—joins GSK, Janssen and Pfizer with 16 academic and SME partners across the E.U., Russia and the U.K.

The five-year…

Mentions:

The European & Developing Countries Clinical Trials Partnership (EDCTP) announced two vaccine awards over the past week.

First, it gave $20 million to the P. falciparum transmission-blocking vaccine (PfTBV) consortium to test and compare three vaccines: two malaria vaccines developed by Denmark’s Statens Serum Institute and another from the U.S. National Institutes of Health. The project started in January of this year and will run until mid-2024 in Burkina Faso, Mali, Guinea and…